Staphyrase® treatment markedly inhibited IL-33-a key mediator of Th2 immune responses in both psoriasis and AD via the activation of ILC2 cells, T cells, and dendritic cells (16)-as well as TSLP expression compared with the Model group (p < 0.05). Here, IL33 is linked to psoriasis.